Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1991-2-25
|
| pubmed:abstractText |
Twenty-one immunodeficiency virus 1 (HIV 1)-positive hemophilic patients were treated with Azidothymidine (AZT) for symptomatic HIV infection. The median observation period was 20.5 months. At 25 months the probability of survival was 82%, the probability of progression of disease from CDC III or IV C2 to IV C1 (AIDS) was 20% in patients on continuous AZT treatment and 50% in patients with interruption of treatment. Three patients developed severe leukopenia and 3 patients severe anemia during AZT treatment. In 1 patient a dose-dependent striking increase of transaminases during AZT treatment was observed. In 7 patients treatment was interrupted, in 1 patient because of anemia, in 1 because of pruritus and in 5 patients because of non-compliance. No significant changes in the consumption of clotting factor concentrates and number of bleeding episodes before and during AZT treatment were noted. We conclude, that both hematological and non-hematological side effects of AZT in HIV 1-infected hemophilic patients are comparable to those seen in other risk groups. AZT does not increase the bleeding tendency in this patient group.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0340-6245
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
13
|
| pubmed:volume |
64
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
108-12
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1980381-Adolescent,
pubmed-meshheading:1980381-Adult,
pubmed-meshheading:1980381-Aged,
pubmed-meshheading:1980381-Blood Cell Count,
pubmed-meshheading:1980381-Blood Coagulation Factors,
pubmed-meshheading:1980381-Blood Transfusion,
pubmed-meshheading:1980381-CD4-Positive T-Lymphocytes,
pubmed-meshheading:1980381-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:1980381-Follow-Up Studies,
pubmed-meshheading:1980381-HIV Infections,
pubmed-meshheading:1980381-HIV-1,
pubmed-meshheading:1980381-Hemophilia A,
pubmed-meshheading:1980381-Humans,
pubmed-meshheading:1980381-Immunophenotyping,
pubmed-meshheading:1980381-Liver,
pubmed-meshheading:1980381-Male,
pubmed-meshheading:1980381-Middle Aged,
pubmed-meshheading:1980381-Patient Compliance,
pubmed-meshheading:1980381-Survival Rate,
pubmed-meshheading:1980381-Zidovudine
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Azidothymidine (AZT) in the treatment of symptomatic HIV-1-infected hemophiliacs.
|
| pubmed:affiliation |
First Department of Medicine, University of Vienna, Austria.
|
| pubmed:publicationType |
Journal Article
|